Washington Trust Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Washington Trust Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28	Closed	-$4.1K	–	718
2023 Q1	$4.1K	Buy	28 +5	+22%	+$740	﹤0.01%	641
2022 Q4	$3.66K	Hold	23	–	–	﹤0.01%	649
2022 Q3	$3K	Buy	23 +3	+15%	+$456	﹤0.01%	800
2022 Q2	$3K	Hold	20	–	–	﹤0.01%	826
2022 Q1	$3K	Hold	20	–	–	﹤0.01%	897
2021 Q4	$3K	Buy	+20	New	+$2.63K	﹤0.01%	922

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Washington Trust Advisors's JAZZ Position: Q2 2023 in Review

Washington Trust Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 28 shares — an estimated $4.1K sold.

Washington Trust Advisors first reported a position in JAZZ in Q4 2021 and held it in 6 quarters. The position peaked at $4.1K in Q1 2023. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Washington Trust Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Washington Trust Advisors sold 28 Jazz Pharmaceuticals shares in Q2 2023, an estimated $4.1K.
Washington Trust Advisors first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Washington Trust Advisors's Jazz Pharmaceuticals position peaked at $4.1K in Q1 2023.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Washington Trust Advisors's 13F filing for Q2 2023, filed 27 Jul 2023.